CONVAT technology is based on pioneering silicon nanophotonic biosensor, the Bimodal Waveguide (BiMW) interferometer. The BiMW biosensor enables label-free real-time detection of pathogens and biomolecules with outstanding sensitivities. The technology will be integrated in a user-friendly point-of-care device for out-of-the-lab and non-specialized operation, employing low amount of sample with none or minimum treatment, and providing reliable results in 15-30 minutes.

The project aims at implementing two main diagnostic approaches:

  • Direct SARS-CoV-2 detection in saliva/respiratory fluids: by targeting the Spike (S) protein of the coronavirus, we will directly capture intact virus particles present in respiratory fluids or saliva of COVID-19 patients. The rapid and ultrasensitive assay will allow early detection of SARS-CoV-2 infection, even in asymptomathic patients, and will deliver quantitative data on the viral load.
  • PCR-free viral genomic analysis: by targeting specific viral RNA sequences, we will identify the coronavirus type and variant without any PCR amplification steps. A multiplexed assay will be implemented for rapid detection of different viruses (alpha-CoVs, beta-CoVs, and others). The genomic biosensor could be used as confirmatory COVID-19 diagnostics, as well as to analyze and control the presence of dangerous viruses in reservoir species.
CONVAT project summary